Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. It develops “off-the-shelf” TCR-guided NK cell therapies (TCR-NK) to treat solid cancers, offering broad cancer detection and scalable treatment. The company is headquartered in Oslo, Norway.